secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K/A
Filed at:   2026-07-31T20:05:13+00:00
Accession:  0001193125-26-328470
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine files pro forma financials for Soleno acquisition; combined net income $294M for H1 2026
--------------------------------------------------------------------------------

- Pro forma combined net income $294.0M ($2.92 basic EPS) for six months ended June 30, 2026.
- Pro forma combined net income $324.5M ($3.26 basic EPS) for year ended Dec 31, 2025.
- Acquisition of Soleno for $53/share added VYKAT XR for Prader-Willi syndrome; funded with $600M credit facility draw, fully repaid by June 30.
- Soleno contributed $94.6M revenue in Q1 2026 and $190.4M in FY2025.
- Preliminary purchase price allocation includes $168.2M inventory step-up amortized over 4-6 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000119312526328470/0001193125-26-328470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000119312526328470/d73154d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-328470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer